reports
Unicycive Therapeutics Announces Full Year 2025 Financial Results and ...
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Uni...
Sight Sciences Secures Order on Post-Trial Motions That Preserves the ...
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent Court preserves jury’s finding of willful infringement by Alcon, and awards past damages to Sight Sciences in excess of $34 million and ongoing royalties through November 2028 MENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care a...
Kraig Biocraft Laboratories Deploys Over 700,000 BAM-1 Alpha Productio...
Kraig Biocraft Laboratories Deploys Over 700,000 BAM-1 Alpha Production Hybrids, Achieving Key Milestone in its Aggressive Scale-Up Plan ANN ARBOR, Mich., March 30, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced the successful deployment of more than 700,000 BAM-1 Alpha production hybrids of its previously reported 1,000,000 egg inventory. These silkworms are now in active production. This achievement underscores the Company's continued execution of its previou...
PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and File...
PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024 Deploys Capital into Cash-Flowing Manufacturing Businesses in Aerospace, Defense and IT PackagingAdvances Dual Myostatin Assets Targeting Muscle Preservation in Potential Combination with GLP-1 Treatments NEWPORT BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“the Company,” “PMGC,” “we,” or “our”) today filed its Annual Report on Form 10-K (“Annual Report”) for the fiscal year ended December 31, 2025 (“FYE ...
Connect Biopharma Announces $20.2 Million Private Placement Financing
Connect Biopharma Announces $20.2 Million Private Placement Financing Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 6,130,000 shares of ...
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic De...
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study – Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to placebo – – Data presented during late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting – – Company to host conference call and webcast today, March 30, 2026 at 8:00 a.m. ET – SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limit...
Signify share repurchase periodic update
Signify share repurchase periodic update Press Release March 30, 2026 Signify share repurchase periodic update Eindhoven, The Netherlands – (Euronext: LIGHT), the world leader in lighting, today announced that it has repurchased 70,000 shares in the period March 23 to March 27, 2026. The shares were repurchased at an average price of EUR 18.05 per share and an aggregate amount of EUR 1.3 million. The repurchases were made as part of the company’s share repurchase program, which was announced on . Signify will use the shares to cover obligations arising from its long-term incentive per...
Oatly to Report First Quarter 2026 Financial Results on April 29, 2026
Oatly to Report First Quarter 2026 Financial Results on April 29, 2026 MALMÖ, Sweden, March 30, 2026 (GLOBE NEWSWIRE) -- Oatly Group AB (Nasdaq: OTLY), the world’s original and largest oat drink company, will report financial results for the first quarter ended March 31, 2026, on Wednesday April 29, 2026 before the U.S. market opens. Oatly will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results. The conference call and simultaneous live webcast can be accessed on Oatly’s Investors website at under “Events.” The webcast will be archived for 30 days....
Changes in the Kalmar Leadership Team
Changes in the Kalmar Leadership Team KALMAR CORPORATION, STOCK EXCHANGE RELEASE, 30 MARCH 2026 AT 2 PM (EEST) Changes in the Kalmar Leadership Team Kalmar Corporation today announces changes in the Kalmar Leadership Team (KLT) designed to enhance the company’s long-term strategic growth and performance. These changes involve the appointment of a new Chief Financial Officer, the departures of the Chief Financial Officer and the President of Services, and the planned search for a new President of Services. Katri Hokkanen (born 1981, M.Sc. Econ.) has been appointed Chief Financial Officer (...
USA Rare Earth Reports Fourth Quarter and Full-Year 2025 Financial Res...
USA Rare Earth Reports Fourth Quarter and Full-Year 2025 Financial Results STILLWATER, Okla., March 30, 2026 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (the Company), an emerging global leader in rare earths, today announced its financial and operational results for the fourth quarter and year ended December 31, 2025. Executive Commentary “2025 was the year that USA Rare Earth set the foundation to execute our integrated rare earth growth strategy,” said Barbara Humpton, CEO of USA Rare Earth. “We acquired the unique and internationally well-known metal and alloy ma...
Connect Biopharma Announces Positive Topline Data from its Phase 1 Stu...
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD – Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV1 with many patients experiencing improvements in airway function of ≥200 mL as early as 15 minutes post-dosing – – The rapid improvement in FEV1 demonstrated with IV rademikibart in this study provides clinical confirmation of preclinical observations that rademikibart has a unique benefic...
Terrestrial Energy Announces Fourth Quarter and Full Year 2025 Results
Terrestrial Energy Announces Fourth Quarter and Full Year 2025 Results Texas A&M University selected commercial IMSR plant for deployment at RELLIS campus U.S. Department of Energy selected both Terrestrial Energy reactor pilot and fuel-line pilot projects for advanced reactor programs NRC Accepted IMSR Principal Design Criteria Including Inherent Reactor Control Mechanisms Completed business combination, raising approximately $292 million in gross proceeds CHARLOTTE, N.C., March 30, 2026 (GLOBE NEWSWIRE) -- Terrestrial Energy Inc. (NASDAQ: IMSR) (“Terrestrial Energy” or “the Compan...
CareCloud Highlights Successful Preferred A Conversion, Progress Towar...
CareCloud Highlights Successful Preferred A Conversion, Progress Toward Capital Structure Simplification, and Reaffirms Growth Outlook SOMERSET, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leading provider of healthcare technology and revenue cycle management solutions, today highlighted the successful continued market absorption of the Q1 2025 conversion of its Series A Preferred Stock (“Preferred A”, formerly traded as CCLDP) into common equity, while reaffirming its previously issued financial guidance and continued c...
Muutoksia Kalmarin johtoryhmässä
Muutoksia Kalmarin johtoryhmässä KALMAR OYJ, PÖRSSITIEDOTE, 30.3.2026 KLO 14.00 (EEST)Muutoksia Kalmarin johtoryhmässä Kalmar Oyj ilmoittaa tänään muutoksista johtoryhmässään (KLT), joiden tarkoituksena on vauhdittaa yhtiön pitkän aikavälin strategista kasvua ja tuloksellisuutta. Muutoksiin kuuluvat uuden talous- ja rahoitusjohtajan nimitys, nykyisen talousjohtajan ja palveluliiketoiminnan johtajan siirtyminen muihin tehtäviin sekä suunniteltu uuden palveluliiketoiminnan johtajan haku. Katri Hokkanen (synt. 1981, KTM) on nimitetty talous- ja rahoitusjohtajaksi (CFO) ja johtoryhmän jäs...
Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment...
Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries 23 claims of U.S. Patent No. 11,435,360 remain valid, supporting Seer's Proteograph® Product Suite REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leader in deep, unbiased proteomic insights, today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23, 2026, in an inter partes review of U.S. Patent No. 11,435,360 B2 (the “’360 Patent”). The inter pa...
Digital Realty Announces Final Close of $3.25 billion U.S. Hyperscale ...
Digital Realty Announces Final Close of $3.25 billion U.S. Hyperscale Data Center Fund Digital Realty also announces expansion of Strategic Private Capital team to build on the recent progress of its funding strategy, support hyperscale customer growth and enable the long-term scalability of PlatformDIGITAL AUSTIN, Texas, March 30, 2026 (GLOBE NEWSWIRE) -- Digital Realty (NYSE: DLR), the world’s largest cloud- and carrier-neutral data center platform, today announced the final close of its inaugural U.S. hyperscale data center fund (the “Fund”), securing $3.25 billion of total equity co...
OROCO ANNOUNCES RESIGNATION OF CEO
OROCO ANNOUNCES RESIGNATION OF CEO VANCOUVER, Canada, March 30, 2026 (GLOBE NEWSWIRE) -- Oroco Resource Corp. (TSX-V: OCO, OTC: ORRCF) (“Oroco” or the “Company”) announces the resignation of Richard Lock as Chief Executive Officer and a director of the Company for personal reasons, effective April 30, 2026. Mr. Lock commented: “I am grateful for the opportunity to have led Oroco since April 2022 and for the dedication of the team in advancing the Santo Tomás Project and the Company's objectives. It has been a privilege to contribute during this important phase of growth and developm...
Smart Share Global Limited Granted Exception by Nasdaq Staff Related t...
Smart Share Global Limited Granted Exception by Nasdaq Staff Related to Filing of Its Interim Report SHANGHAI, March 30, 2026 (GLOBE NEWSWIRE) -- Smart Share Global Limited (Nasdaq: EM) (“Energy Monster” or the “Company”), a consumer tech company providing mobile device charging service, today announced that it has been granted an exception by Nasdaq Staff regarding the filing of a Form 6-K containing an interim balance sheet and income statement for its fiscal half-year ended June 30, 2025 (the “Interim Report”). On January 14, 2026, Nasdaq Staff notified the Company that it did not com...
BioStem Technologies Announces the Publication of its Audited Financia...
BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025 The Company continues its progression towards a Nasdaq uplisting POMPANO BEACH, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has filed its audited consolidated financial statements as of and for the fiscal years ended December 31, 2024 and 2025. The financial statements are available for review in t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.